Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis

BACKGROUND: Numerous first-line immune checkpoint inhibitors (ICI) were developed for patients with advanced non-small cell lung cancer (NSCLC) lacking driver gene mutations. However, this group consists of a heterogeneous patient population, for whom the optimal therapeutic choice is yet to be conf...

Descripción completa

Detalles Bibliográficos
Autores principales: Wenfan, Fu, Manman, Xu, Xingyuan, Shi, Zeyong, Jiang, Jian, Zhao, Lu, Dai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568994/
https://www.ncbi.nlm.nih.gov/pubmed/37841212
http://dx.doi.org/10.1177/20406223231189224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568994/
https://www.ncbi.nlm.nih.gov/pubmed/37841212
http://dx.doi.org/10.1177/20406223231189224

Ejemplares similares